Skip to content
Syngene International logo

Syngene International

SYNGENE NSE
₹417.50 +10.90 (+2.68%)
P/E
76.05
View as Markdown
MCP
Close 4 Nov 2026 ₹417.50 −203.10 −32.7% 1Y
Start ₹620.60

Key Fundamentals

SmallcapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
9.99%
Debt to Equity
0.09
EPS (TTM)
₹5.49
Book Value
₹120.37
Market Cap
—
P/E (TTM)
76.05
P/B
3.47
ROE
7.78%
Dividend Yield
0.31%
EBITDA
₹989 Cr
52W High
₹678.95
52W Low
₹344.45
Day Range
₹404.30 – ₹421.00
Volume
8,12,637

Peer Comparison

Healthcare › Healthcare Technology › Healthcare Research, Analytics & Technology

Syngene International peer comparison
Syngene International (this company)
₹417.5076.05₹16,536 Cr3.470.31%7.78%9.99%₹3,600 Cr₹221 Cr
Indegene
₹617.1037.04₹14,947 Cr4.430.37%14.40%18.80%₹3,813 Cr₹401 Cr
Suven Life Sciences
₹276.10—₹7,549 Cr11.390.00%−81.50%−79.50%₹9 Cr−₹353 Cr
Vimta Labs
₹497.8527.89₹2,195 Cr4.530.41%18.90%25.20%₹419 Cr₹80 Cr
Fabtech Technologies
₹132.309.94₹589 Cr1.340.46%12.50%13.60%₹418 Cr₹49 Cr
Take
₹11.4213.13₹161 Cr5.440.00%16.50%18.50%₹85 Cr₹13 Cr
Median 6 companies₹346.8027.89₹4,872 Cr4.480.34%13.45%16.05%₹419 Cr₹64 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

40 Weak

Data confidence 100/100

Category scores

Quality
50
Average
Returns, margins, earnings quality 22% weight
Valuation
42
Weak
Cheap vs sector & own history 24% weight
Growth
12
Poor
Sales & profit trajectory 9% weight
Financial Health
43
Weak
Solvency, leverage, coverage 9% weight
Momentum
28
Poor
Trend strength, vol-adjusted 12% weight
Ownership
49
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is almost debt free.

Weaknesses

4
  • Stock is trading at 3.15 times its book value
  • The company has delivered a poor sales growth of 11.4% over past five years.
  • Company has a low return on equity of 10.1% over last 3 years.
  • Dividend payout has been low at 12.0% of profits over last 3 years

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish5311
OscillatorsNeutral333
Moving AveragesStrong Bullish208

Key readings

RSI (14)
62.16
Neutral
MACD (12,26,9)
8.11
Bullish
SMA (50)
384.36
Bullish
SMA (200)
426.44
Bearish

As of

Analyst Rating

Based on 8 analysts
BUY75%

6 of 8 analysts rate Buy, 2 Hold, 0 Sell.

As of

BUY
6
75%
HOLD
2
25%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+11.35%
3Y+5.40%
1Y+2.66%
TTM−3.41%

Net profit

Net profit growth by window
5Y−4.78%
3Y−11.93%
1Y−36.09%
TTM−56.43%

Operating cash flow

Operating cash flow growth by window
5Y+5.47%
3Y+3.55%
1Y−21.66%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y−6.41 pp
3Y−4.87 pp
1Y−4.06 pp
TTM−6.63 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2018₹1,423 Cr
Mar 2019₹1,826 Cr
Mar 2020₹2,012 Cr
Mar 2021₹2,184 Cr
Mar 2022₹2,604 Cr
Mar 2023₹3,193 Cr
Mar 2024₹3,489 Cr
Mar 2025₹3,642 Cr
Mar 2026₹3,739 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2018₹305 Cr
Mar 2019₹332 Cr
Mar 2020₹412 Cr
Mar 2021₹405 Cr
Mar 2022₹396 Cr
Mar 2023₹464 Cr
Mar 2024₹510 Cr
Mar 2025₹496 Cr
Mar 2026₹317 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹825 Cr −16.6% vs FY26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 4 Nov 2026
AI opinion · based on fundamentals
Risk high

Syngene International trades at ₹417.5 as of 2026-11-04 with a market cap of ₹16,536 crore and a PE of 76.05x on a TTM EPS of ₹5.49. The stock is down roughly 38% over the past year from a 52-week high of ₹678.95, reflecting a sharp contraction in trailing twelve-month profit (−42%) alongside near-zero debt and a debt-to-equity ratio of just 0.09.

Bull Case 6
  • The company is virtually debt-free with a debt-to-equity ratio of only 0.09, providing significant financial flexibility and low interest-rate risk.
  • The company has been actively reducing its debt levels, strengthening its balance sheet for future capital allocation or expansion.
  • Five-year compounded sales growth stands at 11%, indicating a reasonable top-line expansion trajectory over a medium-term horizon.
  • Price-to-book ratio of 3.47x reflects the market's recognition of Syngene's asset-light CDMO business model and intangible capabilities in research services.
  • Three-year average ROE of 10% and five-year average ROE of 11% demonstrate the company's ability to generate reasonable returns on shareholder equity over longer periods despite recent softness.
  • The contract research and CDMO sector in India benefits from secular tailwinds such as global supply-chain diversification and patent cliffs, positioning Syngene in a structurally growing industry.
Bear Case 8
  • TTM profit has contracted by 42%, signalling a severe earnings decline that underpins the elevated PE of 76.05x.
  • The trailing twelve-month PE of 76.05x is extremely stretched, requiring a sharp earnings recovery just to bring valuations closer to sector norms.
  • Stock price CAGR has been negative across multiple horizons — −38% over 1 year, −18% over 3 years, and −7% over 5 years — reflecting sustained value destruction for shareholders.
  • TTM revenue has declined by 3%, reversing the longer-term growth trend and raising questions about near-term demand visibility.
  • Three-year compounded profit growth is −8%, while five-year compounded profit growth is flat at 0%, showing no meaningful earnings expansion over a substantial period.
  • Current ROE of 6.54% (and last year's 8%) is well below the longer-term averages, indicating deteriorating capital efficiency.
  • Dividend yield is a meagre 0.31% with a payout ratio of only about 12% of profits over the last three years, offering minimal income return to shareholders.
  • Even the 10-year stock CAGR is just 4%, barely keeping pace with inflation and lagging broader market returns over the same period.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

14d ago

TL;DR: Limited recent news flow for Syngene International. The only development is a mid-level executive departure in corporate affairs, which is unlikely to have a material impact on operations or financials. No significant headwinds or positive catalysts are visible from the current news set. Watch for upcoming quarterly results and any client deal announcements for directional cues.

Neutral 1
  • Head of Corp Affairs resigns Sep 21

    Pramuch Goel, Head of Corporate Affairs & Communications, resigned effective September 21, 2026, to pursue other career opportunities.

Quarterly Results

₹ Cr
SYNGENE quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
808
910
854
917
790
891
944
1,018
875
911
917
1,037
736
833
Expenses
596
656
622
600
620
646
660
674
668
711
708
733
645
685
Operating Profit
212
254
232
317
170
245
284
344
206
200
209
303
90.8
—
OPM %
26.22%
27.92%
27.12%
34.56%
21.5%
27.47%
30.05%
33.75%
23.6%
21.91%
22.81%
29.27%
12.34%
—
Other Income
23.6
14.2
25.6
16.1
50.1
16.5
18.3
18.9
17.7
15.4
−55.2
16.2
11.8
—
Interest
10.5
13
10.8
12.9
11.7
13.1
12.4
15.9
11.6
13.2
11.9
12.1
9.6
10
Depreciation
102
105
108
111
107
111
109
106
111
117
114
112
112
112
PBT
123
151
138
209
101
137
181
241
101
85.2
28.4
196
−19.2
47
Tax %
24%
22.69%
19.32%
9.76%
25.27%
22.72%
27.49%
23.78%
14.41%
21.24%
47.18%
24.54%
−53.12%
31.49%
Net Profit
93.4
117
112
189
75.7
106
131
183
86.7
67.1
15
148
−9
32.2
EPS (₹)
2.32
2.9
2.77
4.69
1.88
2.64
3.26
4.55
2.15
1.67
0.37
3.67
−0.22
—

Sep 2026: from the results filed on 27 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
SYNGENE profit and loss, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,423
1,826
2,012
2,184
2,604
3,193
3,489
3,642
3,739
3,600
Expenses
949
1,289
1,394
1,507
1,861
2,251
2,472
2,598
2,817
2,797
Operating Profit
474
537
618
678
743
942
1,017
1,045
921
803
OPM %
33%
29%
31%
31%
29%
30%
29%
29%
25%
22%
Other Income
53
75
153
94
75
63
77
101
−9
−12
Interest
23
32
35
28
24
45
47
53
49
47
Depreciation
131
164
219
274
310
366
426
433
453
454
PBT
372
415
517
469
484
594
621
660
411
290
Tax %
18%
20%
20%
14%
18%
22%
18%
25%
23%
—
Net Profit
305
332
412
405
396
464
510
496
317
221
EPS (₹)
7.64
8.29
10.3
10.12
9.88
11.57
12.69
12.33
7.86
5.49
Div. Payout %
7%
3%
0%
0%
10%
11%
10%
10%
16%
—

Balance Sheet

₹ Cr
SYNGENE balance sheet, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
200
200
400
400
401
401
402
402
403
Reserves
1,520
1,768
1,776
2,421
2,897
3,217
3,856
4,324
4,436
Borrowings
787
813
773
893
1,022
815
555
578
458
Other Liabilities
681
922
1,214
1,169
1,245
1,398
1,339
1,491
1,757
Total Liabilities
3,189
3,704
4,163
4,883
5,564
5,831
6,152
6,796
7,055
Fixed Assets
1,030
1,377
2,020
2,201
2,393
2,667
2,850
2,802
3,000
CWIP
155
274
234
237
346
177
838
1,266
1,046
Investments
158
716
776
702
1,034
918
548
647
741
Other Assets
1,846
1,337
1,133
1,743
1,790
2,069
1,916
2,081
2,268
Total Assets
3,189
3,704
4,163
4,883
5,564
5,831
6,152
6,796
7,055

Cash Flow

₹ Cr
SYNGENE cash flow, annual, ₹ crore
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
446
630
677
701
581
824
1,042
1,168
915
Investing
−349
−646
−424
−629
−611
−653
−494
−744
−839
Financing
−79
−72
−226
58
−31
−342
−551
−142
−215
Net Cash Flow
18
−88
28
130
−62
−172
−4
281
−138
Free Cash Flow
82
47
34
255
105
305
553
398
547
CFO/EBITDA
111
135
127
116
92
102
115
123
107

Ratios

SYNGENE financial ratios, annual
Particulars Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
68
68
72
79
71
61
46
53
50
Inventory Days
82
30
18
41
87
141
94
60
56
Days Payable
195
154
156
167
113
109
100
136
138
Cash Conversion Cycle
−44
−56
−66
−47
45
92
40
−23
−32
Working Capital Days
−48
−103
−172
−66
−43
−14
−27
−51
−68
ROCE %
—
17%
17%
14%
13%
15%
15%
13%
10%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Syngene International insights

63 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 52.59%
  • DIIs 29.30%
  • FIIs 10.14%
  • Public 6.27%
  • Others 1.70%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Syngene International

What does Syngene International Ltd do?
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS).
Where is Syngene International Ltd (SYNGENE) listed?
Syngene International Ltd trades as SYNGENE on the NSE and under code 539268 on the BSE.
Which sector does Syngene International Ltd belong to?
Syngene International Ltd is classified under the Healthcare sector, in the Healthcare Technology industry.
What is the PE ratio of Syngene International Ltd?
Syngene International Ltd trades at a PE ratio of 76.05 as of 4 Nov 2026, on earnings per share of ₹5.49, against a book value of ₹120.37 per share.
What is the 52-week high and low of Syngene International Ltd?
Over the last 52 weeks Syngene International Ltd has traded between ₹344.45 and ₹678.95 as of 4 Nov 2026.
Does Syngene International Ltd pay dividends?
Syngene International Ltd has a dividend yield of 0.31%.
What is the Return on Equity (ROE) of Syngene International Ltd?
Syngene International Ltd reported a return on equity of 7.78%. Its debt-to-equity ratio is 0.09.

Company Information

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.

Website syngeneintl.com
CEO Mr. Peter James Jonathan Bains
Employees 6,533
Listed 11 Aug 2015
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SYNGENE.md for Syngene International Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month